Review of the ATAC study: Tamoxifen versus anastrozole in early-stage breast cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 12, 2008, Pages 1871-1881

  Needleman, Sarah J ^a   Tobias, Jeffrey S ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant therapy; Anastrozole; Aromatase inhibitor; Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; FRACTURE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSSIFICATION; OSTEOLYSIS; OVERALL SURVIVAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; BREAST TUMOR; EARLY DIAGNOSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EARLY DIAGNOSIS; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 61449365697     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.12.1871     Document Type: Review

References (46)

1. Early Breast Cancer Triallists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
2. Early Breast Cancer Triallists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randoised trials. Lancet 365, 1687-1617 (2005).
3. The American College of Obstetricians and Gynaecologists. Tamoxifen and endometrial cancer. Obstet. Gynecol. 95, 2585-2588 (2000).
4. Nabholtz JM, Buzdar A, Pollak M et al. Anastrolzole is superior to tamoxifen as first-line therapy for advanced breast cancer in post menopausal women: results of a North American multicentre randomised trial. J. Clin. Oncol. 18, 3758-3776 (2000).
5. Bonneterre J, Thurlmann B, Robertson JF et al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 post menopausal women: results of the taoxifen or Arimidex randomised group efficacy and tolerability study. J. Clin. Oncol. 18, 3748-3757 (2000).
6. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
7. Buzdar A, On behalf of ATAC trialists' group. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy ocerview. J. Steroid Biochem. Mol. Biol. 86, 399-403 (2003).
8. The ATAC Trialists' Group. Anastrozole alone or in combination with taoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC trial efficacy and safety update analyses. Cancer 98 (9), 1802-1810 (2003).
9. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
10. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet 9, 45-53 (2008).
11. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J. Cli. Oncol. 22(21), 4261-4271 (2004).
12. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res. Treat. 100(3), 273-284 (2006).
13. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams J. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2 year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J. Bone Miner. Res. 21(8), 1215-1223 (2006).
14. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial (18233230) J. Clin. Oncol. 26(7), 1051-1057 (2008).
15. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the anti oestrogen tamoxifen on bone mineral density in normal late menopausal women. Am. J. Med. 99, 636-641 (1995).
16. Resch A, Biber E, Seifert M, Resch H. Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol. 37, 661-661 (1998).
17. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and torimefene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 83, 1158-1162 (1998).
18. Kristensen B, Ejlertsen B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: a randomised study. J. Clin. Oncol. 12, 992-997 (1994).
19. Ward RI, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and prioximal femoral bone loss in early postmenopausal women. Bone Miner. 22, 87-94 (1993).
20. Powles TJ, Hickish T, Kannis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptimetry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78-84 (1996).
21. Duffy S, Jackson TL, Lansdown M et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum. Reprod. 21(2), 545-553 (2006).
22. Bartelli G, Pronzato P, Amoroso D et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res. Treat. 12, 307-310 (1988).
23. Dewar J, Nabhotlz JMA, Bonneterre J et al. The effect of anastrozole (Arimidex) on serum lipids - data from a randomized comparison of amastrozole (AN) vs tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cncer Res. Treat. 4(Suppl.), S51 (2000).
24. Love RR, Wiebe DA, Feyzi JM, Newcombe PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst. 86, 1534-1539 (1994).
25. Morales M, Santana N, Soria A et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res. Treat. 40, 265-270 (1996).
26. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am. Heart J. 2(153), 182-188 (2007).
27. Elisaf MS, Bairaktari ET, Nicolaides C et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer 37, 1510-1513 (2001).
28. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
29. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7(8), 633-643 (2006).
30. Smith IE., Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicancer double-blind randomized trial. J. Clin. Oncol. 23(22), 4842-4844 (2005).
31. Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P, Dowsett M. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant theraphy in the impact trial. Ann. Oncol. 16(10), 1632-1638 (2005).
32. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am. Heart J. 153(2), 182-188 (2007).
33. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5 year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone in combination) trial. Br. J. Cancer 97, 152-161 (2007).
34. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for post menopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res. Treat. 106(2), 229-238 (2007).
35. Hilner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101(6), 1311-1322 (2004).
36. Jones SE. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin. Breast Cancer 6(Supply. 2) S41-S44 (2006).
37. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455-462 (2005).
38. Jonat W, Gnant M, Boccardo F et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7(12), 991-996 (2006).
39. Coombes RC, Paridaens R, Jassem J. First mature analysis of the Intergroup Exemestane Study ASCO, Annual Meeting Proceedings Part 1. J. Clin. Oncol. 24, 18S LBA527 (2006).
40. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J. Natl Cancer Inst. 97, 1262-1271 (2005).
41. Ferguson MJ, Dewar JA. Tamoxifen beyond 5 years - patients' decisions regarding entry to the aTTom trial. Eur. J. Cancer 38(14), 1857-1859 (2002).
42. Davies C, Nomura Y, Ohashi Y. Adjuvant tamoxifen duration: more large-scale randomized evidence is needed. Gan. To Kagaku Ryoho 24(10), 1203-1209 (1997).
43. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of TTR in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 24(9), 1481-1482 (2006).
44. Tovey S, Dunne B, Witton CJ, Forysth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitions in invasive breast cancer? Clin. Cancer Res. 11(13), 4835-4842 (2005).
45. Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 17(5), 818-826 (2006).
46. Dowsett M, Allred C, Knox J et al. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. J. Clin. Oncol. 26(7), 1059-1065 (2008).